Tower Research Capital (TRC)’s Contineum Therapeutics CTNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$51.1K Buy
3,806
+1,642
+76% +$24.5K ﹤0.01% 3218
2026
Q2
$35.5K Buy
2,164
+1,433
+196% +$18.8K ﹤0.01% 3037
2026
Q1
$9.5K Buy
731
+607
+490% +$8.14K ﹤0.01% 3924
2025
Q4
$1.42K Sell
124
-1,551
-93% -$17.7K ﹤0.01% 4696
2025
Q3
$19.7K Sell
1,675
-5,780
-78% -$46.6K ﹤0.01% 3324
2025
Q2
$29.6K Buy
7,455
+6,097
+449% +$26.5K ﹤0.01% 3404
2025
Q1
$9.48K Buy
1,358
+415
+44% +$3.78K ﹤0.01% 3769
2024
Q4
$13.8K Buy
943
+463
+96% +$7.33K ﹤0.01% 3504
2024
Q3
$9.19K Buy
480
+386
+411% +$7.4K ﹤0.01% 3893
2024
Q2
$1.66K Buy
+94
New +$1.51K ﹤0.01% 5116

Other funds holding CTNM

Tower Research Capital (TRC)'s CTNM Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Contineum Therapeutics (CTNM) stake by 76% in Q3 2026, buying an estimated $24.5K and bringing the position to 3,806 shares worth $51.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3218.

Tower Research Capital (TRC) first reported a position in CTNM in Q2 2024 and has held it in 10 quarters since. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Tower Research Capital (TRC) held 3,806 shares of Contineum Therapeutics worth $51.1K as of Q3 2026.
  • Tower Research Capital (TRC) bought 1,642 Contineum Therapeutics shares in Q3 2026, an estimated $24.5K.
  • Contineum Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3218 holding.
  • Tower Research Capital (TRC) first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.